Related Experiment Video
Updated: Jul 19, 2026

Screening for Melanoma Modifiers using a Zebrafish Autochthonous Tumor Model
Published on: November 13, 2012
Taming NEMO to slay cancer cells
Kimberly A Scata1, Wafik S El-Deiry
1Department of Medicine (Hematology/Oncology), The Institute for Translational Medicine and Therapeutics, The Abramson Comprehensive Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Understanding how cells survive DNA damage is key to improving chemotherapy. The ATM protein directly phosphorylates NEMO, activating the NF-kappaB pathway, which promotes cell survival against DNA damage.
Area of Science:
- Cellular biology
- Molecular oncology
- Signal transduction
Background:
- Chemotherapy efficacy is limited by cellular survival mechanisms following DNA damage.
- The Nuclear Factor-kappaB (NF-kappaB) pathway is a key mediator of cell survival, counteracting pro-apoptotic signals.
- Regulation of the NF-kappaB pathway in response to DNA damage has remained incompletely understood.
Purpose of the Study:
- To elucidate the regulatory mechanisms linking DNA damage to NF-kappaB activation.
- To investigate the role of ATM in the DNA damage response pathway concerning NF-kappaB signaling.
Main Methods:
- Investigated the interaction between DNA damaging agents and the NF-kappaB signal transduction cascade.
- Utilized molecular biology techniques to study protein phosphorylation and cellular localization.
Main Results:
- Demonstrated that ATM directly phosphorylates NEMO upon DNA damage.
- Showed that ATM is translocated to the cytoplasm with NEMO.
- Confirmed that this interaction leads to the activation of IKK and subsequent NF-kappaB activation.
Conclusions:
- ATM-mediated phosphorylation of NEMO is a critical step in activating the NF-kappaB survival pathway following DNA damage.
- This finding provides a mechanistic link between DNA damage response and cell survival signaling.
- Understanding this pathway offers potential targets for enhancing chemotherapy efficacy by inhibiting cell survival mechanisms.
Related Concept Videos
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer
Treatment Resistant Cancers
Targeted Cancer Therapies
There are several types of targeted therapies against specific...
Targeted Cancer Therapies
There are several types of targeted therapies against specific...

